发明授权
US5858689A Isolated peptides derived from the gage tumor rejection antigen
precursor and uses thereof
失效
衍生自量规肿瘤排斥抗原前体的分离的肽及其用途
- 专利标题： Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
- 专利标题（中）： 衍生自量规肿瘤排斥抗原前体的分离的肽及其用途
-
申请号： US531662申请日： 1995-09-21
-
公开(公告)号： US5858689A公开(公告)日： 1999-01-12
- 发明人: Pierre van der Bruggen , Benoit van den Eynde , Olivier DeBacker , Thierry Boon-Falleur
- 申请人： Pierre van der Bruggen , Benoit van den Eynde , Olivier DeBacker , Thierry Boon-Falleur
- 申请人地址： NY New York
- 专利权人： Ludwig Institute for Cancer Research
- 当前专利权人： Ludwig Institute for Cancer Research
- 当前专利权人地址： NY New York
- 主分类号： G01N33/48
- IPC分类号： G01N33/48 ; A61K38/00 ; C07K7/06 ; C07K7/08 ; C07K14/47 ; C07K14/525 ; C12N15/09 ; C12N15/12 ; C12Q1/00 ; C07K7/00
摘要：
A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
公开/授权文献
信息查询
